MAPK3 and lung carcinoma: By combining the PB1 domain of PKCι, blocking its interaction with Par6, inhibiting the downstream Rac1–Pak–Mek1/2–Erk1/2 signaling pathway, thereby inhibiting lung cancer cell proliferation.